Advertisement

Topics

Shire may spin off hyperactivity drugs, raises forecasts

13:22 EDT 3 Aug 2017 | Reuters

LONDON (Reuters) - Shire, the London-listed pharmaceutical firm built up by acquisitions, said it might spin off its hyperactivity drugs business into a separate company and focus solely on rare disease treatments.

Original Article: Shire may spin off hyperactivity drugs, raises forecasts

NEXT ARTICLE

More From BioPortfolio on "Shire may spin off hyperactivity drugs, raises forecasts"

Quick Search
Advertisement
 

Relevant Topic

Alliances, mergers acquisitions and partnerships
BioPortfolio's alliances, mergers acquisitions and partnerships channel provides the latest news and corporate information on the global bio-pharmaceutical industry.